ReviewNanotheranostics2021
Noninvasive Imaging of Cancer Immunotherapy.
Review in Nanotheranostics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers.Molecules (Basel, Switzerland) · 2021Pooled it
- Imaging the hallmarks of cancer.Nature reviews. Cancer · 2026Review
- [Overview of CAR-T cell therapy : What the radiologist should know].Radiologie (Heidelberg, Germany) · 2026Review
- Granzyme B-Targeting Quenched Activity-Based Probes for Assessing Tumor Response to Immunotherapy.Journal of the American Chemical Society · 2025Article
- Article
- PET in the characterization of immune diseases and development of therapeutics.Oxford open immunology · 2025Review
- Imaging of tumor-associated macrophage dynamics during immunotherapy using a CD163-specific nanobody-based immunotracer.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Why Current Detection of Vascular Calcification Falls Short and How to Improve on It.TH open : companion journal to thrombosis and haemostasis · 2024Review
- The role of CD8 PET imaging in guiding cancer immunotherapy.Frontiers in immunology · 2024Review
- Computational Gene Expression and Network Analysis of Myc Reveal Insights into Its Diagnostic and Prognostic Role in Subtypes of Renal Cancer.Applied biochemistry and biotechnology · 2023Article
- The diagnosis, classification, and treatment of sarcoma in this era of artificial intelligence and immunotherapy.Cancer communications (London, England) · 2022Review
- Opportunities for improving brain cancer treatment outcomes through imaging-based mathematical modeling of the delivery of radiotherapy and immunotherapy.Advanced drug delivery reviews · 2022Review
- Radionuclide Imaging of Cytotoxic Immune Cell Responses to Anti-Cancer Immunotherapy.Biomedicines · 2022Review
- Visualizing T-Cell Responses: The T-Cell PET Imaging Toolbox.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Review
- Dose escalation biodistribution, positron emission tomography/computed tomography imaging and dosimetry of a highly specific radionuclide-labeled non-blocking nanobody.EJNMMI research · 2021Article
- Microbial proteases: ubiquitous enzymes with innumerable uses.3 Biotech · 2021Review
- The expression and prognostic value of REXO4 in hepatocellular carcinoma.Journal of gastrointestinal oncology · 2021Article
- Nanobodies for Medical Imaging: About Ready for Prime Time?Biomolecules · 2021Review
- Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives.Frontiers in pharmacology · 2021Review
- Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy.Journal of immunology research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Immunotherapy has revolutionized the treatment of several malignancies. Notwithstanding the encouraging results, many patients do not respond to treatments. Evaluation of the efficacy of treatments is challenging and robust methods to predict the response to treatment are not yet available. The outcome of immunotherapy results from changes that treatment evokes in the tumor immune landscape. Therefore, a better understanding of the dynamics of immune cells that infiltrate into the tumor microenvironment may fundamentally help in addressing this challenge and provide tools to assess or even predict the response. Noninvasive imaging approaches, such as PET and SPECT that provide whole-body images are currently seen as the most promising tools that can shed light on the events happening in tumors in response to treatment. Such tools can provide critical information that can be used to make informed clinical decisions. Here, we review recent developments in the field of noninvasive cancer imaging with a focus on immunotherapeutics and nuclear imaging technologies and will discuss how the field can move forward to address the challenges that remain unresolved.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.